liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?
Division of Cardiology, San Francisco General Hospital, San Francisco, CA, USA .
Cardiology Section, Denver VA Medical Center, Denver, CO, USA.
Linköping University, Department of Medical and Health Sciences, Internal Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
2001 (English)In: Current controlled trials. Cardiovascular medicine (Online), ISSN 1468-6708, E-ISSN 1468-6694, Vol. 2, no 3, 111-114 p.111-114 p.Article in journal, Editorial material (Other academic) Published
Abstract [en]

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) Trial tested the hypothesis that intensive lowering of cholesterol with atorvastatin (80 mg/day) initiated 24-96 h after an acute coronary syndrome would, over 4 months, reduce the incidence of the composite endpoint of death, nonfatal infarction, resuscitated cardiac arrest, and recurrent symptomatic myocardial ischemia with new objective symptoms requiring emergency rehospitalization. This primary composite endpoint was reduced from 17.4% to 14.8% (P = 0.048) among the 3086 patients enrolled. The results of MIRACL suggest that patients with acute coronary syndromes should begin to receive this treatment before leaving hospital, irrespective of baseline levels of low-density lipoprotein-cholesterol.

Place, publisher, year, edition, pages
London, UK: BioMed Central, 2001. Vol. 2, no 3, 111-114 p.111-114 p.
Keyword [en]
atorvastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, myocardial infarction, unstable angina
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-48980DOI: 10.1186/cvm-2-3-111ISI: 000173941200003OAI: oai:DiVA.org:liu-48980DiVA: diva2:269876
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Olsson, Anders G

Search in DiVA

By author/editor
Olsson, Anders G
By organisation
Internal MedicineFaculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
In the same journal
Current controlled trials. Cardiovascular medicine (Online)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 50 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf